NEGGRAM Drug Patent Profile
When do Neggram patents expire, and what generic alternatives are available?
Neggram is a drug marketed by Sanofi Aventis Us and is included in two NDAs.
The generic ingredient in NEGGRAM is nalidixic acid. There is one drug master file entry for this compound. Additional details are available on the nalidixic acid profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for NEGGRAM?
- What are the global sales for NEGGRAM?
- What is Average Wholesale Price for NEGGRAM?
Summary for NEGGRAM
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Patent Applications: | 5,896 |
| DailyMed Link: | NEGGRAM at DailyMed |
US Patents and Regulatory Information for NEGGRAM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | NEGGRAM | nalidixic acid | SUSPENSION;ORAL | 017430-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sanofi Aventis Us | NEGGRAM | nalidixic acid | TABLET;ORAL | 014214-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sanofi Aventis Us | NEGGRAM | nalidixic acid | TABLET;ORAL | 014214-005 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sanofi Aventis Us | NEGGRAM | nalidixic acid | TABLET;ORAL | 014214-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NEGGRAM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | NEGGRAM | nalidixic acid | TABLET;ORAL | 014214-002 | Approved Prior to Jan 1, 1982 | 3,590,036 | ⤷ Start Trial |
| Sanofi Aventis Us | NEGGRAM | nalidixic acid | SUSPENSION;ORAL | 017430-001 | Approved Prior to Jan 1, 1982 | 3,590,036 | ⤷ Start Trial |
| Sanofi Aventis Us | NEGGRAM | nalidixic acid | TABLET;ORAL | 014214-004 | Approved Prior to Jan 1, 1982 | 3,590,036 | ⤷ Start Trial |
| Sanofi Aventis Us | NEGGRAM | nalidixic acid | TABLET;ORAL | 014214-005 | Approved Prior to Jan 1, 1982 | 3,590,036 | ⤷ Start Trial |
| Sanofi Aventis Us | NEGGRAM | nalidixic acid | SUSPENSION;ORAL | 017430-001 | Approved Prior to Jan 1, 1982 | 4,105,659 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for NEGGRAM
See the table below for patents covering NEGGRAM around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Belgium | 767505 | ⤷ Start Trial | |
| Austria | 246157 | ⤷ Start Trial | |
| Austria | 252248 | ⤷ Start Trial | |
| Belgium | 611000 | ⤷ Start Trial | |
| Brazil | 6134479 | ⤷ Start Trial | |
| Switzerland | 410960 | Verfahren zur Herstellung von Benzazocinderivaten | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch